Covered recipient · General Payments record
MARYAM KHAWARI
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$81.13
6 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $81.13 | 6 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $29.19 | 2 |
| Janssen Pharmaceuticals, Inc | $26.77 | 2 |
| GlaxoSmithKline, LLC. | $14.04 | 1 |
| GE HEALTHCARE | $11.13 | 1 |
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARYAM KHAWARI
NPI 1346381365 · CMS profile ID 1170349
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
KATY, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARYAM KHAWARI, NPI 1346381365, CMS profile ID 1170349. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MARYAM KHAWARI, NPI 1346381365, CMS profile ID 1170349. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MARYAM KHAWARI, NPI 1346381365, CMS profile ID 1170349, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
6 matching records · $81.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–6 of 6.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $10.86 | 11/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658524415 | CMS |
| Janssen Pharmaceuticals, Inc | $12.23 | 09/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658837665 | CMS |
| GE HEALTHCARE | $11.13 | 08/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698470313 | CMS |
| Janssen Pharmaceuticals, Inc | $14.54 | 06/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658837661 | CMS |
| Janssen Biotech, Inc. | $18.33 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658524409 | CMS |
| GlaxoSmithKline, LLC. | $14.04 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671410499 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $602,203.64 | 55 |
| PY2024 | Principal investigator | $249,711.62 | 17 |
| PY2023 | Principal investigator | $51,621.05 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
55 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $292.92 | 12/31/2025 | Non-covered Recipient Entity WCG CLINICAL INC | A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202532703 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 12/31/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202535377 |
| Principal investigator 1 | ABBVIE INC. | $2,050.00 | 12/04/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202528800 |
| Principal investigator 1 | ABBVIE INC. | $2,592.10 | 12/04/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202529004 |
| Principal investigator 1 | ARGENX US, INC. | $1,200.00 | 11/12/2025 | Non-covered Recipient Entity WCG Clinical Inc | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237161618 |
| Principal investigator 1 | Amgen Inc. | $37,149.54 | 11/12/2025 | Non-covered Recipient Entity PHARMASEEK LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome | No dispute reported | 06/30/2026 | 1246646489 |
| Principal investigator 1 | ABBVIE INC. | $9,732.55 | 11/04/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202520909 |
| Principal investigator 1 | ABBVIE INC. | $3,800.00 | 10/30/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202519767 |
| Principal investigator 1 | ABBVIE INC. | $5,605.60 | 10/09/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202515469 |
| Principal investigator 1 | ABBVIE INC. | $4,295.00 | 10/09/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202515471 |
| Principal investigator 1 | ABBVIE INC. | $1,985.00 | 08/05/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501272 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $20,150.00 | 08/01/2025 | Non-covered Recipient Entity PHARMASEEK LLC | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225335999 |
| Principal investigator 1 | Amgen Inc. | $41,163.26 | 07/18/2025 | Non-covered Recipient Entity PHARMASEEK LLC | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome | No dispute reported | 06/30/2026 | 1246646484 |
| Principal investigator 1 | ABBVIE INC. | $6,635.00 | 07/02/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202496283 |
| Principal investigator 1 | ABBVIE INC. | $15,147.00 | 06/26/2025 | Non-covered Recipient Entity WCG CLINICAL INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202493149 |
| Principal investigator 1 | ARGENX US, INC. | $77.40 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156337 |
| Principal investigator 1 | ARGENX US, INC. | $3.15 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156341 |
| Principal investigator 1 | ARGENX US, INC. | $13.25 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156344 |
| Principal investigator 1 | ARGENX US, INC. | $214.80 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156348 |
| Principal investigator 1 | ARGENX US, INC. | $1.75 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156353 |
| Principal investigator 1 | ARGENX US, INC. | $238.75 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156356 |
| Principal investigator 1 | ARGENX US, INC. | $75.20 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156359 |
| Principal investigator 1 | ARGENX US, INC. | $143.20 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156363 |
| Principal investigator 1 | ARGENX US, INC. | $35.80 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156367 |
| Principal investigator 1 | ARGENX US, INC. | $5.60 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156372 |
| Principal investigator 1 | ARGENX US, INC. | $477.50 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156377 |
| Principal investigator 1 | ARGENX US, INC. | $668.50 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156380 |
| Principal investigator 1 | ARGENX US, INC. | $21.35 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156385 |
| Principal investigator 1 | ARGENX US, INC. | $85.40 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156389 |
| Principal investigator 1 | ARGENX US, INC. | $132.50 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156392 |
| Principal investigator 1 | ARGENX US, INC. | $5.25 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156395 |
| Principal investigator 1 | ARGENX US, INC. | $155.25 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156400 |
| Principal investigator 1 | ARGENX US, INC. | $21.35 | 06/18/2025 | Non-covered Recipient Entity R & H Clinical Research Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237156404 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 06/12/2025 | Non-covered Recipient Entity WCG CLINICAL INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202491055 |
| Principal investigator 1 | Eli Lilly and Company | $2,500.00 | 06/06/2025 | Non-covered Recipient Entity WCG CLINICAL INC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187893298 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 06/04/2025 | Non-covered Recipient Entity WCG Clinical Inc | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237161604 |
| Principal investigator 1 | ARGENX US, INC. | $1,600.00 | 06/04/2025 | Non-covered Recipient Entity WCG Clinical Inc | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237161606 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 06/04/2025 | Non-covered Recipient Entity WCG Clinical Inc | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237161610 |
| Principal investigator 1 | ARGENX US, INC. | $12,000.00 | 06/04/2025 | Non-covered Recipient Entity WCG Clinical Inc | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237161614 |
| Principal investigator 1 | ABBVIE INC. | $663.00 | 05/22/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202485799 |
| Principal investigator 1 | Amgen Inc. | $65,655.58 | 05/21/2025 | Non-covered Recipient Entity PHARMASEEK LLC | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246646480 |
| Principal investigator 1 | Amgen Inc. | $16,372.44 | 05/21/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246647016 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 05/06/2025 | Non-covered Recipient Entity WCG CLINICAL INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202481467 |
| Principal investigator 1 | ABBVIE INC. | $487.35 | 04/23/2025 | Non-covered Recipient Entity WCG CLINICAL INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202478679 |
| Principal investigator 1 | ABBVIE INC. | $90.00 | 04/17/2025 | Non-covered Recipient Entity WCG CLINICAL INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202477596 |
| Principal investigator 1 | ABBVIE INC. | $2,678.50 | 04/03/2025 | Non-covered Recipient Entity WCG CLINICAL INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202472397 |
| Principal investigator 1 | Amgen Inc. | $255,084.79 | 04/01/2025 | Non-covered Recipient Entity PHARMASEEK LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246646497 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/27/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202466778 |
| Principal investigator 1 | Amgen Inc. | $15,204.04 | 03/19/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH-777 S FRY RD | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State | No dispute reported | 06/30/2026 | 1246647012 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 03/06/2025 | Non-covered Recipient Entity WCG CLINICAL INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202457447 |
| Principal investigator 1 | ABBVIE INC. | $413.20 | 02/13/2025 | Non-covered Recipient Entity WCG CLINICAL INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202451255 |
| Principal investigator 1 | ABBVIE INC. | $3,786.75 | 02/05/2025 | Non-covered Recipient Entity WCG CLINICAL INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202445031 |
| Principal investigator 1 | Amgen Inc. | $41,111.03 | 01/21/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246647024 |
| Principal investigator 1 | Amgen Inc. | $17,604.49 | 01/15/2025 | Non-covered Recipient Entity R & H CLINICAL RESEARCH | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome | No dispute reported | 06/30/2026 | 1246647020 |
| Principal investigator 1 | ABBVIE INC. | $2,678.50 | 01/02/2025 | Non-covered Recipient Entity WCG CLINICAL INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202434820 |